AOD-9604 is a modified growth-hormone fragment developed around a lipolysis hypothesis. Preclinical plausibility and early development do not override the larger null obesity trial.
What the record shows
- The human efficacy record is weaker than many product summaries imply.
- ClinicalTrials.gov did not contain AOD-9604 studies in FDA’s 2024 search.
- Sequence/form identity and lot testing cannot establish a therapeutic effect.
The identity and evidence boundary
A material page can accurately discuss sequence identity, analytical methods and the historical research hypothesis. It should also surface the null development result close to any mention of weight-loss research.
What belongs in the material record
For lot review, confirm sequence, molecular form, mass, purity method, quantitative peptide content and batch linkage. Those controls establish material characterization, not clinical effectiveness.
Editorial rule
Use the exact intervention name, model, population and endpoint from the cited record. Do not convert an association, mechanism, animal result, approved finished-drug record or analytical test into a claim about an unrelated catalog lot.
Sources & editorial method
The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- FDA Evaluation of AOD-9604-Related Bulk Drug SubstancesU.S. FDA. December 4, 2024 Pharmacy Compounding Advisory Committee briefing document.
- AOD-9604 development reviewWilding J. Current Opinion in Investigational Drugs. 2004. PMID 15134286.
- FDA December 2024 PCAC meeting recordRegulatory meeting context.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
